Calmodulin antagonists inhibit insulin-stimulated GLUT4 (glucose transporter 4) translocation by preventing the formation of phosphatidylinositol 3,4,5-trisphosphate in 3T3L1 adipocytes
Cm. Yang et al., Calmodulin antagonists inhibit insulin-stimulated GLUT4 (glucose transporter 4) translocation by preventing the formation of phosphatidylinositol 3,4,5-trisphosphate in 3T3L1 adipocytes, MOL ENDOCR, 14(2), 2000, pp. 317-326
It has been previously reported that calmodulin plays a regulatory role in
the insulin stimulation of glucose transport. To examine the basis for this
observation, we examined the effect of a panel of calmodulin antagonists t
hat demonstrated a specific inhibition of insulin-stimulated glucose transp
orter 4 (GLUT4) but not insulin- or platelet-derived growth factor (PDGF)-s
timulated GLUT1 translocation in 3T3L1 adipocytes. These treatments had no
effect on insulin receptor autophosphorylation or tyrosine phosphorylation
of insulin receptor substrate 1 (IRS1). Furthermore, IRS1 or phosphotyrosin
e antibody immunoprecipitation of phosphatidylinositol (PI) 3-kinase activi
ty was not affected. Despite the marked insulin and PDGF stimulation of PI
3-kinase activity, there was a near complete inhibition of protein kinase B
activation. Using a fusion protein of the Grp1 pleckstrin homology (PH) do
main with the enhanced green fluorescent protein, we found that the calmodu
lin antagonists prevented the insulin stimulation of phosphatidylinositol 3
,4,5-trisphosphate [PI(3,4,5)P3] formation in vivo. Similarly, although PDG
F stimulation increased PI 3-kinase activity in in vitro immunoprecipitatio
n assays, there was also no significant formation of PI(3,4,5)P3 in vivo. T
hese data demonstrate that calmodulin antagonists prevent insulin-stimulate
d GLUT4 translocation by inhibiting the in vivo production of PI(3,4,5)P3 w
ithout directly affecting IRS1- or phosphotyrosine-associated PI 3-kinase a
ctivity. This phenomenon is similar to that observed for the PDGF stimulati
on of 3T3L1 adipocytes.